THX Pharma Appoints Julien Veys as Deputy CEO

Julien Veys' Professional Background

Julien Veys joined THX Pharma in January 2016, the statement notes. He has successively held the positions of Chief Business Development Officer, and then Chief Operating Officer since January 2025. According to the company, he has contributed to several key operations, including the IPO of Theranexus on the Euronext Growth in 2017, the licensing acquisition of the Batten-1 program in 2019 from the Beyond Batten Disease Foundation, and the licensing out of the TX01 program in 2024 to Exeltis, a subsidiary of Insud Pharma. Prior to joining THX Pharma, Julien Veys worked at the biotechnology company Trophos from 2005 to 2015, where he held several strategic roles up to Chief Business Development Officer. He notably contributed to raising 17 million euros in funding and the acquisition of Trophos by Roche for 470 million euros, according to the document. A graduate in science from the University of Aix-Marseille, he also holds an MBA from HEC Paris and sits on the company's board of directors.

Strategic Phase of THX Pharma

According to the group, this appointment is part of THX Pharma's new strategic phase focused on the registration, early access, and international marketing of its drugs for rare neurological diseases. The CEO, Mathieu Charvériat, states in the release that Julien Veys' track record and expertise in strategic development and executing key agreements are assets to support the group's transition towards a model focused on the registration and marketing of its drug candidates, TX01 and Batten-1. THX Pharma is a pharmaceutical company specializing in the treatment of rare neurological diseases. Its first drug, TX01, will soon be marketed in Europe by Exeltis, as well as in the United States, Canada, and Australia, targeting Niemann-Pick disease type C and Gaucher disease. The second drug, Batten-1, targets the juvenile form of Batten disease.

THX Pharma's Additional Resources

THX Pharma also has an antisense oligonucleotide platform developed with specialized laboratories in the field of rare neurological diseases, according to the company. The company, whose commercial name is Theranexus, is listed on the Euronext Growth market in Paris under the mnemonic ALTHX. The Board of Directors, according to a universal registration document filed with the Financial Markets Authority on April 29, 2025, approved this strategic realignment. The company also announced in November 2025 that it had raised approximately 7.8 million euros in a capital increase with preferential subscription rights, intended to fund the development, registration, and marketing of its drug candidates. The available cash was 1,979,000 euros as of September 30, 2025, compared to 2,124,000 euros on June 30, 2025.